# AAVantgarde Bio

**Canonical:** https://apis.io/providers/aavantgardebio/  
**Website:** https://www.aavantgarde.com/en/  
**APIs profiled:** 0

AAVantgarde Bio is a clinical-stage biotechnology company headquartered in Milan, Italy, developing next-generation adeno-associated virus (AAV) gene therapies for inherited retinal diseases with high unmet need. Founded in 2021 by Prof. Alberto Auricchio, the company has built two proprietary vector platforms — dual hybrid and dual intein — that overcome the DNA cargo capacity limit of a single AAV vector by splitting a large expression cassette across two AAV8 vectors that recombine inside the target cell. Its lead programs are AAVB-081 for retinitis pigmentosa due to Usher syndrome type 1B (LUCE-1 Phase 1/2, the first dual AAV gene therapy tested clinically in an ocular indication) and AAVB-039 for ABCA4-associated Stargardt disease (CELESTE Phase 1/2), which holds FDA Fast Track and Orphan Drug designation. The company raised a EUR 61 million Series A and closed a USD 141 million Series B. AAVantgarde publishes no public API, developer program or machine-readable contract; this profile records what its public web surface actually serves.

## Kin Score — 11.6 / 100 (emerging)

Scored 2026-09-25 under rubric 0.23.0. Trend: flat (-1.2 from 12.8).

| Facet | Score |
|---|---|
| Discoverability | 55.4 |
| Contract Quality | 0.0 |
| Contract Governance | 18.2 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 2.4 |
| Access Clarity | 10.5 |

Regulatory layer — **Health**: 21.1 (matched via tags).

## Agent readiness — 10.8 (agent-aware)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | served |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |
| Delegated Identity | served |
| Protected Resource Metadata | no |
| Dynamic Client Registration | no |
| Agentic Commerce | no |

## Security (2)

- **Aavantgardebio Domain Security** — TLSv1.3 · HSTS · DMARC
- **Aavantgardebio Vulnerability Disclosure** — Hackerone · security.txt · contact published

## Tags

Company, Biotechnology, Gene Therapy, Life Sciences, Pharmaceuticals, Clinical Trials, Ophthalmology, Rare Disease, Healthcare, Italy

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/aavantgardebio/). Scores are computed from the provider's own public artifacts under a published rubric.